CORTEX PHARMACEUTIC Performance
| PHXDelisted Stock | USD 4.35 0.00 0.00% |
On a scale of 0 to 100, CORTEX PHARMACEUTIC holds a performance score of 6. The firm shows a Beta (market volatility) of 0.32, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, CORTEX PHARMACEUTIC's returns are expected to increase less than the market. However, during the bear market, the loss of holding CORTEX PHARMACEUTIC is expected to be smaller as well. Please check CORTEX PHARMACEUTIC's total risk alpha, downside variance, as well as the relationship between the Downside Variance and day median price , to make a quick decision on whether CORTEX PHARMACEUTIC's price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in CORTEX PHARMACEUTIC are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating technical indicators, CORTEX PHARMACEUTIC showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 806.3 K |
CORTEX |
CORTEX PHARMACEUTIC Relative Risk vs. Return Landscape
If you would invest 394.00 in CORTEX PHARMACEUTIC on April 27, 2025 and sell it today you would earn a total of 41.00 from holding CORTEX PHARMACEUTIC or generate 10.41% return on investment over 90 days. CORTEX PHARMACEUTIC is generating 0.3026% of daily returns assuming volatility of 3.5366% on return distribution over 90 days investment horizon. In other words, 31% of stocks are less volatile than CORTEX, and above 94% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
CORTEX PHARMACEUTIC Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CORTEX PHARMACEUTIC's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CORTEX PHARMACEUTIC, and traders can use it to determine the average amount a CORTEX PHARMACEUTIC's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0856
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PHX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.54 actual daily | 31 69% of assets are more volatile |
Expected Return
| 0.3 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average CORTEX PHARMACEUTIC is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CORTEX PHARMACEUTIC by adding it to a well-diversified portfolio.
CORTEX PHARMACEUTIC Fundamentals Growth
CORTEX Stock prices reflect investors' perceptions of the future prospects and financial health of CORTEX PHARMACEUTIC, and CORTEX PHARMACEUTIC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CORTEX Stock performance.
| Return On Equity | 0.0555 | |||
| Return On Asset | 0.0185 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | (0.04) % | |||
| Current Valuation | 182.81 M | |||
| Shares Outstanding | 37.92 M | |||
| Price To Earning | 21.21 X | |||
| Price To Book | 1.31 X | |||
| Price To Sales | 4.58 X | |||
| Revenue | 34.27 M | |||
| EBITDA | 15.32 M | |||
| Cash And Equivalents | 3.4 M | |||
| Cash Per Share | 0.12 X | |||
| Total Debt | 30.2 M | |||
| Debt To Equity | 0.30 % | |||
| Book Value Per Share | 3.44 X | |||
| Cash Flow From Operations | 18.08 M | |||
| Earnings Per Share | 0.19 X | |||
| Total Asset | 163.92 M | |||
| Retained Earnings | 77.07 M | |||
| Current Asset | 6.57 M | |||
| Current Liabilities | 4.47 M | |||
About CORTEX PHARMACEUTIC Performance
Evaluating CORTEX PHARMACEUTIC's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if CORTEX PHARMACEUTIC has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CORTEX PHARMACEUTIC has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
PHX Minerals Inc. operates as a natural gas and oil mineral company in the United States. PHX Minerals Inc. was founded in 1926 and is based in Oklahoma City, Oklahoma. Phx Minerals operates under Oil Gas EP classification in the United States and is traded on New York Stock Exchange. It employs 20 people.Things to note about CORTEX PHARMACEUTIC performance evaluation
Checking the ongoing alerts about CORTEX PHARMACEUTIC for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CORTEX PHARMACEUTIC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CORTEX PHARMACEUTIC is not yet fully synchronised with the market data | |
| CORTEX PHARMACEUTIC had very high historical volatility over the last 90 days | |
| CORTEX PHARMACEUTIC has a very high chance of going through financial distress in the upcoming years | |
| About 69.0% of the company shares are owned by institutional investors | |
| On 4th of June 2025 CORTEX PHARMACEUTIC paid $ 0.04 per share dividend to its current shareholders |
- Analyzing CORTEX PHARMACEUTIC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CORTEX PHARMACEUTIC's stock is overvalued or undervalued compared to its peers.
- Examining CORTEX PHARMACEUTIC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CORTEX PHARMACEUTIC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CORTEX PHARMACEUTIC's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CORTEX PHARMACEUTIC's stock. These opinions can provide insight into CORTEX PHARMACEUTIC's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in CORTEX Stock
If you are still planning to invest in CORTEX PHARMACEUTIC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CORTEX PHARMACEUTIC's history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |